Mendus is missing a company thread so lets get one started 
Mendus is a pharmaceutical development company focusing cancer maintenance therapies:
Their focus is to address tumor recurrence. After cancer is treated, residual cancer cells can bring the cancer back - this is what Mendus is trying to prevent:
Mendus’ current clinical pipeline is furthest away in AML (Acute myeloid leukemia):
CEO Erik Manting & CMO Jeroen Rovers gave an update on Mendus in a recent audiocast (from November), which you can watch here 
Lets continue discussion on Mendus here in English/Swedish 
I’ll also tag our analyst @antti.siltanen who currently has active coverage on another company within immuno-oncology (Faron Pharmaceuticals)